RE: Interesting Conference8 Aug 2018 03:45
Morning nomlungu,
It is the subject matters chosen by Fierce Biotech which makes the conference so interesting, and i am sure the presenters will do justice to the event.
It seems to be more and more in the spotlight now, how best the checkpoint inhibitors can be used in combination with other immunotherapies., making it very relevant to SCB1/2 forthcoming trials. I have said on a few occasions we are entering this trial at what i consider to be a good time. There have been a raft of failures which everybody must have learnt a fair bit from. Lets hope that is the case and i do think standout data from such a trial will indeed standout given that
It is vital to have a good understanding of the Oncology market in general, to even hazard a guess as to our potential worth, and that is why i do post links that i deem of interest and likewise enjoy links found by others and posted up. Given that i was very surprised to see hotwings/inanaco posts removed, which i saw briefly. I hope they can both post free of such animosty, which i reckon ADMIN picked up on, rather the content. That is a shame for all of us, the subject matter was interesting.